Asset Details
Do you wish to reserve the book?
The illusion of safety: A report to the FDA on AI healthcare product approvals
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The illusion of safety: A report to the FDA on AI healthcare product approvals
Do you wish to request the book?
The illusion of safety: A report to the FDA on AI healthcare product approvals
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The illusion of safety: A report to the FDA on AI healthcare product approvals
2025
Overview
Artificial intelligence is rapidly transforming healthcare, offering promising advancements in diagnosis, treatment, and patient outcomes. However, concerns regarding the regulatory oversight of artificial intelligence driven medical technologies have emerged, particularly with the U.S. Food and Drug Administration’s current approval processes. This paper critically examines the U.S. Food and Drug Administration’s regulatory framework for artificial intelligence powered healthcare products, highlighting gaps in safety evaluations, post-market surveillance, and ethical considerations. Artificial intelligence’s continuous learning capabilities introduce unique risks, as algorithms evolve beyond their initial validation, potentially leading to performance degradation and biased outcomes. Although the U.S. Food and Drug Administration has taken steps to address these challenges, such as artificial intelligence/machine learning-based software as a medical device action plan and proposed regulatory adjustments, significant weaknesses remain, particularly in real-time monitoring, transparency and bias mitigation. This paper argues for a more adaptive, community-engaged regulatory approach that mandates extensive post-market evaluations, requires artificial intelligence developers to disclose training data sources, and establishes enforceable standards for fairness, equity, and accountability. A patient-centered regulatory framework must also integrate diverse perspectives to ensure artificial intelligence technologies serve all populations equitably. By fostering an agile, transparent, and ethics-driven oversight system, the U.S. Food and Drug Administration can balance innovation with patient safety, ensuring that artificial intelligence-driven medical technologies enhance, rather than compromise, healthcare outcomes.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
